NOTION-2: first TAVI vs. SAVR randomised trial in younger low-risk patients with severe tricuspid or bicuspid aortic valve stenosis

Christopher Cook interviews Ole de Backer about this study he presented at EuroPCR 2024: It provides further data concerning the 1-year outcome of younger AS patients with tricuspid valve anatomy treated with TAVI compared to SAVR. TAVI and SAVR showed similar rates of the primary endpoint at 1 year, but this interpretation is limited by the small sample size.
It also provides a “word of caution” concerning the use of TAVI in younger AS patients with bicuspid valve anatomy: dedicated trials comparing optimal TAVI with SAVR in younger patients with bicuspid aortic valve stenosis are now required.

This interview was filmed at EuroPCR 2024: see more videos here.